Pan‐cyclin‐dependent kinase inhibition is a potential treatment for adenoid cystic carcinoma that downregulates the MYB::NFIB fusion and induces tumor regression
Cancer Communications · 2025-12 · 45 (12) · 1734-1738
DOI: 10.1002/cac2.70079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 12.11.2025. Verfasst von Junchi Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Herbert and Karin Jacobsson Foundation, Stiftelserna Wilhelm och Martina Lundgrens, Sjöbergstiftelsen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Laboratory Medicine, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Otorhinolaryngology, Oral and Maxillofacial Surgery, Region Västra Götaland, NU-Hospital Group, Trollhättan, Sweden.
ORCID-Profile: André Fehr, Mattias K Andersson
Förderung
- Herbert and Karin Jacobsson Foundation
- Stiftelserna Wilhelm och Martina Lundgrens
- Sjöbergstiftelsen
- Stiftelsen Lars Hiertas Minne
- Cancerfonden
- The Swedish state under an agreement between the Swedish government and country councils, the ALF agreement
- Stiftelsen Assar Gabrielssons Fond
Zitieren
APA
Huang, J., Larsson, P., Kakay Afshari, M., Tejera Nevado, P., Tešan Tomić, T., Fehr, A., Jäwert, F., Stenman, G., & Andersson, M. K. (2025). Pan‐cyclin‐dependent kinase inhibition is a potential treatment for adenoid cystic carcinoma that downregulates the MYB::NFIB fusion and induces tumor regression. Cancer Communications, 45(12), 1734-1738. https://doi.org/10.1002/cac2.70079
Vancouver
Huang J, Larsson P, Kakay Afshari M, Tejera Nevado P, Tešan Tomić T, Fehr A, et al. Pan‐cyclin‐dependent kinase inhibition is a potential treatment for adenoid cystic carcinoma that downregulates the MYB::NFIB fusion and induces tumor regression. Cancer Communications. 2025;45(12):1734-1738. doi:10.1002/cac2.70079
BibTeX
@article{Huang2025,
author = {Huang, Junchi and Larsson, Peter and Kakay Afshari, Maryam and Tejera Nevado, Paloma and Tešan Tomić, Tajana and Fehr, André and Jäwert, Fredrik and Stenman, Göran and Andersson, Mattias K},
title = {Pan‐cyclin‐dependent kinase inhibition is a potential treatment for adenoid cystic carcinoma that downregulates the MYB::NFIB fusion and induces tumor regression},
journal = {Cancer Communications},
year = {2025},
volume = {45},
number = {12},
pages = {1734--1738},
doi = {10.1002/cac2.70079}
}
EUVIMED